Compare FTCI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | RANI |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 106.9M |
| IPO Year | 2021 | 2021 |
| Metric | FTCI | RANI |
|---|---|---|
| Price | $5.04 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $10.80 | $7.50 |
| AVG Volume (30 Days) | 90.5K | ★ 886.0K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $1,633,000.00 |
| Revenue This Year | $65.44 | $274.77 |
| Revenue Next Year | $45.97 | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | 58.85 |
| 52 Week Low | $3.21 | $0.39 |
| 52 Week High | $12.75 | $3.87 |
| Indicator | FTCI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 39.33 |
| Support Level | $4.20 | $0.70 |
| Resistance Level | $5.31 | $1.05 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 45.98 | 21.64 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.